Citizens JMP reiterates CRISPR Therapeutics stock rating on in-vivo progress

Citizens JMP reiterated its Market Outperform rating and $86 price target for CRISPR Therapeutics (CRSP), citing progress in its in-vivo therapeutic programs and strong financial position with $1.86 billion in cash. The firm highlights recent data from the CTX310 program showing best-in-class reductions in ANGPTL3 protein levels and notes the valuation of competitor Verve Therapeutics as a potential upside indicator. Additionally, Clear Street upgraded CRSP to Buy with a $45 price target, following positive Q1 2025 results, while the company advances its pipeline through partnerships like the one with Sirius Therapeutics for SRSD107.

Analysis

Citizens JMP has reiterated its Market Outperform rating and an $86.00 price target for CRISPR Therapeutics (NASDAQ:CRSP), highlighting a significant potential upside from the current $43.19 price, largely attributed to the company's in-vivo therapeutic programs which are perceived to have received minimal valuation contribution thus far. Recent data from CRISPR's CTX310 program demonstrated dose-dependent decreases in ANGPTL3 protein levels, achieving what Citizens JMP termed "best-in-class peak TG and LDL reductions" for cardiovascular applications. This progress is supported by a robust financial position, with InvestingPro data indicating CRSP holds more cash than debt, a strong current ratio of 15.64, and a reported cash reserve of $1.86 billion. Further bolstering the positive outlook, Clear Street upgraded CRSP from Hold to Buy with a $45 price target following positive first-quarter 2025 results. The valuation of competitor Verve Therapeutics, exceeding $1 billion for similar indications, is cited as a benchmark suggesting potential upside for CRISPR Therapeutics as its in-vivo pipeline advances. An upcoming catalyst is the anticipated first-in-human update from CTX320, the company’s second cardiovascular program targeting Lp(a), expected later this month. Additionally, a strategic partnership with Sirius Therapeutics to co-develop SRSD107, a novel siRNA therapy for thromboembolic disorders, is projected to reach pivotal trials next year, indicating an expansion of CRSP's portfolio beyond its initial focus areas which may not yet be reflected in its current valuation.

Key Decisions for Investors

• Investors should consider the significant valuation gap between CRISPR Therapeutics' current price and Citizens JMP's $86 target, supported by promising clinical data from CTX310 and a strong $1.86 billion cash position, while acknowledging the stock's notable volatility reflected in the broad analyst target range of $32 to $268.
• Upcoming catalysts, particularly the first-in-human data from the CTX320 program expected this month and progress in the SRSD107 pivotal trials with Sirius Therapeutics next year, are critical inflection points that could materially impact the stock's valuation.
• The company's in-vivo pipeline, currently viewed by analysts as undervalued, presents a substantial opportunity for growth; therefore, diligent monitoring of clinical trial results and pipeline advancements is warranted for assessing long-term potential.